Featured Press Releases

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

The merger with NLS Pharmaceutics was approved by Kadimastem shareholders

The merger with NLS Pharmaceutics was approved by Kadimastem shareholders

  • 29 Jan 2025

NLS Pharmaceutics Ltd. a Swiss clinical-stage biopharmaceutical company focused on the discovery...

Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

A convenient and cost-effective way to treat sickle cell disease may be offered by Vascarta

A convenient and cost-effective way to treat sickle cell disease may be offered by Vascarta's patented transdermal drug candidate

Carterra unveils Carterra Ultra™, its most sensitive biosensor platform, advancing fragment and small molecule drug discovery

Carterra unveils Carterra Ultra™, its most sensitive biosensor platform, advancing fragment and small molecule drug discovery

BIZENGRI® (Zenocutuzumab-zbco) Wins FDA Approval for NRG1 Fusion-Positive Cholangiocarcinoma, Says Partner Therapeutics

BIZENGRI® (Zenocutuzumab-zbco) Wins FDA Approval for NRG1 Fusion-Positive Cholangiocarcinoma, Says Partner Therapeutics

AVANTIK Appoints Jeffrey Waldman as Chief Executive Officer

AVANTIK Appoints Jeffrey Waldman as Chief Executive Officer

  • Avantik
  • 10 Aug 2026
BioVigil Reaches 1 Billion Hand Hygiene Opportunities, Marking a Major Milestone in Patient Safety and Infection Prevention

BioVigil Reaches 1 Billion Hand Hygiene Opportunities, Marking a Major Milestone in Patient Safety and Infection Prevention

  • BioVigil
  • 10 Aug 2026
Bruker Announces Majority Stake in MIMETAS to Accelerate Drug Discovery and Development Using Human Physiology-Relevant Models

Bruker Announces Majority Stake in MIMETAS to Accelerate Drug Discovery and Development Using Human Physiology-Relevant Models

  • Bruker Corporation
  • 10 Aug 2026
U.S. FDA Accepts sBLA for ENFLONSIA™ to Expand RSV Indication to High-Risk Children Under Two

U.S. FDA Accepts sBLA for ENFLONSIA™ to Expand RSV Indication to High-Risk Children Under Two

  • Merck & Co., Inc
  • 06 Aug 2026
Takeda

Takeda's ORZEYFUL™ Receives U.S. FDA Approval for Narcolepsy Type 1

  • Takeda Pharmaceutical Company Limited
  • 05 Aug 2026
Why the Pharmacy System Rewards the Wrong Results: It Is Working as Designed

Why the Pharmacy System Rewards the Wrong Results: It Is Working as Designed

  • SHARx
  • 04 Aug 2026

Most Popular
August   2026
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31            

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.